Publication Name	World Journal of Gastroenterology
Manuscript ID	28868
Country	Israel

Received	2016-07-20 10:05
Peer-Review Started	2016-07-21 11:10
To Make the First Decision	2016-09-05 14:36
Return for Revision	2016-09-06 09:26
Revised	2016-09-23 04:15
Second Decision	2016-10-21 18:18
Accepted by Journal Editor-in-Chief	2016-10-22 01:30
Accepted by Executive Editor-in-Chief	2016-10-27 17:19
Articles in Press	2016-10-27 17:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-11-09 09:23
Publish the Manuscript Online	2016-11-18 15:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Allergy
Manuscript Type	Editorial
Article Title	Possible therapeutic role of IgE blockade in irritable bowel syndrome
Manuscript Source	Invited Manuscript
All Author List	Eli Magen and Tinatin Chikovani
Funding Agency and Grant Number
Corresponding Author	Eli Magen, MD, Medicine C Department, Allergy and Clinical Immunology Unit, Barzilai Medical Center, Ben Gurion University of Negev, Ashkelon 78100, Israel. allergologycom@gmail.com
Key Words	IgE; Omalizumab; Irritable bowel syndrome; Anti-inflammatory; Irritable bowel syndrome with diarrhea
Core Tip	Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder diagnosed. A growing body of research suggests that mast cells (MCs) releasing histamine in the colonic mucosa might contribute to the etiology and/or symptomatology of IBS. Blockade of the high-affinity type-Ⅰ?IgE Fc receptors on MCs by omalizumab has been observed as an effective therapy in 2 patients with IBS. We suggest that anti-IgE antibody therapy might be an attractive therapeutic option for functional bowel disorders.
Publish Date	2016-11-18 15:13
Citation	Magen E, Chikovani T. Possible therapeutic role of IgE blockade in irritable bowel syndrome. World J Gastroenterol 2016; 22(43): 9451-9456
URL	http://www.wjgnet.com/1007-9327/full/v22/i43/9451.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i43.9451

Full Article (PDF)	WJG-22-9451.pdf
Full Article (Word)	WJG-22-9451.doc
Manuscript File	28868-Review.docx
Answering Reviewers	28868-Answering reviewers.pdf
Audio Core Tip	28868-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	28868-Conflict-of-interest statement.pdf
Copyright License Agreement	28868-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	28868-Language certificate.pdf
Peer-review Report	28868-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	28868-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	28868-Scientific misconduct check.pdf
Scientific Editor Work List	28868-Scientific editor work list.pdf